A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Bladder cancer; Lung cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms Basket
- 10 Jun 2017 Biomarkers information updated
- 09 Jun 2017 Planned number of patients changed from 72 to 100.
- 02 Jun 2017 Primary end-point (Overall response rate (ORR) in patients with HER2 mutant lung cancers) has been met, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.